Gene
PMM2
| Entrez Gene ID | 5373 (See on NCBI) |
| Description | phosphomannomutase 2 |
| Gene Synonyms | CDG1, CDG1a, CDGS, PMI, PMI1, PMM 2 |
| Node consisting of this Gene | PMM2 LOC100130283///PMM2 |
Networks including this gene
| GSE10072_top8000 - GSE10072 - SiGN-BN NNSR | Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival |
| GSE10780_top8000 - GSE10780 - SiGN-BN NNSR | Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue |
| GSE10797_top8000 - GSE10797 - SiGN-BN NNSR | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
| GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE10927_top8000 - GSE10927 - SiGN-BN NNSR | Human adrenocortical carcinomas (33), adenomas (22), and normal adrenal cortex (10), on Affymetrix HG_U133_plus_2 arrays |
| GSE11482_top8000 - GSE11482 - SiGN-BN NNSR | Rhabdoid Tumor: Gene Expression Clues to Pathogenesis and Potential Therapeutic Targets |
| GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE11729_top8000 - GSE11729 - SiGN-BN NNSR | H1299 EGF and Iressa stimulation |
| GSE12453_top8000 - GSE12453 - SiGN-BN NNSR | Origin and pathogenesis of lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis |
| GSE12682_top8000 - GSE12682 - SiGN-BN NNSR | Expression data from Human Kidney (HK) samples |
| GSE12945_top8000 - GSE12945 - SiGN-BN NNSR | Expression data from colorectal cancers |
| GSE13168_top8000 - GSE13168 - SiGN-BN NNSR | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13507_top8000 - GSE13507 - SiGN-BN NNSR | Predective Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer |
| GSE13591_top8000 - GSE13591 - SiGN-BN NNSR | Integrated genomics approach to detect allelic imbalances in multiple myeloma |
| GSE13861_top8000 - GSE13861 - SiGN-BN NNSR | Gene expression signature-based novel prognostic risk score in gastric cancer |
| GSE14786_top8000 - GSE14786 - SiGN-BN NNSR | Gene expression analysis of cancer-related fatigue in whole blood from breast cancer survivors |
| GSE14879_top8000 - GSE14879 - SiGN-BN NNSR | Gene expression study of anaplastic large cell lymphomas: cellular origin, pathogenesis and relation to Hodgkin lymphoma |
| GSE14925_top8000 - GSE14925 - SiGN-BN NNSR | Expression data from Non small cell lung cancer cell lines |
| GSE15212_top8000 - GSE15212 - SiGN-BN NNSR | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
| GSE15395_top8000 - GSE15395 - SiGN-BN NNSR | HCT116 tumor cells treated with a CDK inhibitor |
| GSE15641_top8000 - GSE15641 - SiGN-BN NNSR | Gene signatures of progression and metastasis in renal cell cancer |
| GSE15765_top8000 - GSE15765 - SiGN-BN NNSR | Identification of cholangiocarcinoma-like gene expression traits in hepatocellular carcinoma |
| GSE15852_top8000 - GSE15852 - SiGN-BN NNSR | Expression data from human breast tumors and their paired normal tissues |
| GSE16391_top8000 - GSE16391 - SiGN-BN NNSR | GGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial |
| GSE16757_top8000 - GSE16757 - SiGN-BN NNSR | Gene expression study in hepatocellular carcinoma |
| GSE17764_top8000 - GSE17764 - SiGN-BN NNSR | Expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients |
| GSE18088_top8000 - GSE18088 - SiGN-BN NNSR | Correlation of molecular profiles and clinical outcome of stage UICC II colon cancer patients |
| GSE18105_top8000 - GSE18105 - SiGN-BN NNSR | Stage II and stage III colorectal cancer |
| GSE18684_top8000 - GSE18684 - SiGN-BN NNSR | Fine mapping of androgen regulated genes in LNCaP cells |
| GSE19069_top8000 - GSE19069 - SiGN-BN NNSR | Molecular signatures in peripheral T-cell lymphoma (PTCL) |
| GSE19274_top8000 - GSE19274 - SiGN-BN NNSR | Expression profiling in Neuroblastoma Primary tumors and Cell lines |
| GSE19417_top8000 - GSE19417 - SiGN-BN NNSR | Human esophageal adenocarcinomas |
| GSE20181_top8000 - GSE20181 - SiGN-BN NNSR | Letrozole (Femara) early and late responses to treatment |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20271_top8000 - GSE20271 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE21122_top8000 - GSE21122 - SiGN-BN NNSR | Whole-transcript expression data for soft-tissue sarcoma tumors and control normal fat specimens |
| GSE21510_top8000 - GSE21510 - SiGN-BN NNSR | Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer |
| GSE22541_top8000 - GSE22541 - SiGN-BN NNSR | Expression data from pulmonary metastases and primary tumors of clear-cell renal cell carcinoma (ccRCC) with different disease-free survivals |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23177_top8000 - GSE23177 - SiGN-BN NNSR | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23806_top8000 - GSE23806 - SiGN-BN NNSR | Expression data of glioblastoma stem-like (GS) cell lines, conventional glioma cell lines and primary tumors |
| GSE23988_top8000 - GSE23988 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE24185_top8000 - GSE24185 - SiGN-BN NNSR | Gene transcription signature of obesity in breast cancer |
| GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE26549_top8000 - GSE26549 - SiGN-BN NNSR | Gene Expression Profiling Predicts the Development of Oral Cancer |
| GSE26599_top8000 - GSE26599 - SiGN-BN NNSR | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE26712_top8000 - GSE26712 - SiGN-BN NNSR | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE27155_top8000 - GSE27155 - SiGN-BN NNSR | Human thyroid adenomas, carcinomas, and normals |
| GSE27480_top8000 - GSE27480 - SiGN-BN NNSR | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE2912_top8000 - GSE2912 - SiGN-BN NNSR | Molecular classification of multiple myeloma |
| GSE29354_top8000 - GSE29354 - SiGN-BN NNSR | Mesothelioma tumor gene expression profiles |
| GSE29683_top8000 - GSE29683 - SiGN-BN NNSR | Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma Genesis [human tumor/cell line data] |
| GSE2990_top8000 - GSE2990 - SiGN-BN NNSR | Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis |
| GSE30929_top8000 - GSE30929 - SiGN-BN NNSR | Whole-transcript expression data for liposarcoma |
| GSE31279_top8000 - GSE31279 - SiGN-BN NNSR | Decoding differentially regulated epithelial and stromal pathways in colorectal cancer |
| GSE3149_top8000 - GSE3149 - SiGN-BN NNSR | Ovarian Cancer Dataset |
| GSE31547_top8000 - GSE31547 - SiGN-BN NNSR | MSKCC-A Primary Lung Cancer Specimens |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE32448_top8000 - GSE32448 - SiGN-BN NNSR | CPDR tumor-benign 80 genechip dataset |
| GSE3960_top8000 - GSE3960 - SiGN-BN NNSR | Classification of neuroblastoma by integrating gene expression pattern with regional alterations in DNA copy number |
| GSE4122_top8000 - GSE4122 - SiGN-BN NNSR | Gene Expression Analysis of Ovarian Samples |
| GSE4290_top8000 - GSE4290 - SiGN-BN NNSR | Expression data of glioma samples from Henry Ford Hospital |
| GSE5107_top8000 - GSE5107 - SiGN-BN NNSR | Distinct Transcription Profiles of Primary and Secondary Glioblastomas |
| GSE5460_top8000 - GSE5460 - SiGN-BN NNSR | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE5846_top8000 - GSE5846 - SiGN-BN NNSR | NCI-60 Cancer Cell Line |
| GSE5847_top8000 - GSE5847 - SiGN-BN NNSR | Tumor and stroma from breast by LCM |
| GSE6008_top8000 - GSE6008 - SiGN-BN NNSR | Human ovarian tumors and normal ovaries |
| GSE6365_top8000 - GSE6365 - SiGN-BN NNSR | Distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| GSE6401_top8000 - GSE6401 - SiGN-BN NNSR | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6691_top8000 - GSE6691 - SiGN-BN NNSR | Gene expression profiling of B lymphocytes and plasma cells from WaldenstrÖm’s macroglobulinemia. |
| GSE6764_top8000 - GSE6764 - SiGN-BN NNSR | Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma |
| GSE8057_top8000 - GSE8057 - SiGN-BN NNSR | Expression data from ovarian cancer cells with time-course and concentration-profiles |
| GSE8218_top8000 - GSE8218 - SiGN-BN NNSR | Gene expression data from prostate cancer samples |
| GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
| GSE9992_top8000 - GSE9992 - SiGN-BN NNSR | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
(78 networks)
